Scarica l'app Stockscreener
10.78
0.28%
-0.03
Dopo l'orario di chiusura:
10.45
-0.33
-3.06%
Precedente Chiudi:
$10.81
Aprire:
$10.78
Volume 24 ore:
188.43K
Relative Volume:
0.58
Capitalizzazione di mercato:
$572.31M
Reddito:
-
Utile/perdita netta:
$-83.74M
Rapporto P/E:
-6.6957
EPS:
-1.61
Flusso di cassa netto:
$-64.98M
1 W Prestazione:
-0.74%
1M Prestazione:
+10.68%
6M Prestazione:
-32.12%
1 anno Prestazione:
-48.62%
Intervallo 1D:
$10.63
$11.11
Intervallo di 1 settimana:
$10.08
$11.19
Portata 52W:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Confronta TYRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
10.78 | 547.20M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
What analysts say about Tyra Biosciences Inc. stockHigh-octane gains - Autocar Professional
Tyra Biosciences (NASDAQ:TYRA) Trading Down 3% – Here’s Why - Defense World
Tyra Biosciences Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
What drives Tyra Biosciences Inc. stock priceExponential return rates - jammulinksnews.com
Is Tyra Biosciences Inc. a good long term investmentRemarkable growth - jammulinksnews.com
Why Tyra Biosciences Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
Achondroplasia Breakthrough? Tyra Biosciences CEO Reveals Latest Treatment Progress at UBS Fireside Chat - Stock Titan
June Brings on Some Huge Insider Buying - AOL.com
What analysts say about HOOK stockPhenomenal capital appreciation - jammulinksnews.com
Trading (TYRA) With Integrated Risk Controls - news.stocktradersdaily.com
What drives Diana Shipping Inc. stock priceSuperior profit margins - Jammu Links News
What drives Third Harmonic Bio Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com
Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize
What makes Tyra Biosciences Inc. stock price move sharplySmart Return Focused Trading - Newser
How Tyra Biosciences Inc. stock performs during market volatilityInsider Strategy Insight - Newser
Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st
Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress
Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest
New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan
Where are the Opportunities in (TYRA) - news.stocktradersdaily.com
Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):